Ouathek Ouerfelli

6.9k total citations · 1 hit paper
62 papers, 4.1k citations indexed

About

Ouathek Ouerfelli is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Ouathek Ouerfelli has authored 62 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Molecular Biology, 12 papers in Organic Chemistry and 12 papers in Oncology. Recurrent topics in Ouathek Ouerfelli's work include Glycosylation and Glycoproteins Research (9 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Ouathek Ouerfelli is often cited by papers focused on Glycosylation and Glycoproteins Research (9 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Ouathek Ouerfelli collaborates with scholars based in United States, France and Japan. Ouathek Ouerfelli's co-authors include Guangli Yang, Samuel J. Danishefsky, Maureen F. Zakowski, Yixuan Gong, William Pao, Neal Rosen, Romel Somwar, Michael K. Rosen, Laura Sepp‐Lorenzino and Mark G. Kris and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Ouathek Ouerfelli

60 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

2006 664 citations Marissa N. Balak, Yixuan Gong et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Ouathek Ouerfelli

Since Specialization

Citations

This map shows the geographic impact of Ouathek Ouerfelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ouathek Ouerfelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ouathek Ouerfelli more than expected).

Fields of papers citing papers by Ouathek Ouerfelli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ouathek Ouerfelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ouathek Ouerfelli. The network helps show where Ouathek Ouerfelli may publish in the future.

Co-authorship network of co-authors of Ouathek Ouerfelli

This figure shows the co-authorship network connecting the top 25 collaborators of Ouathek Ouerfelli. A scholar is included among the top collaborators of Ouathek Ouerfelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ouathek Ouerfelli. Ouathek Ouerfelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	GPA33-pretargeted radioimmunotherapy with mono- and bivalent DOTA-based Lu-177-labeled radiohaptens in a mouse orthotopic liver xenograft model of metastatic human colorectal cancer 2025 ·Theranostics ·(unknown), Edward K. Fung, Sang Gyu Lee, Sébastien Monette, Hong Xu, Hong-Fen Guo, (unknown), Ouathek Ouerfelli, Achim A. Jungbluth, Heiko Schöder, Steven M. Larson, Nai‐Kong V. Cheung, Sarah M. Cheal, Darren R. Veach	2
2	CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment 2021 ·Molecular Cancer Therapeutics ·Tomohiro Fujiwara, Mohamed A. Yakoub, Andrew Chandler, Alexander B. Christ, Guangli Yang, Ouathek Ouerfelli, Vinagolu K. Rajasekhar, Aki Yoshida, Hiroya Kondo, Toshiaki Hata, Hiroshi Tazawa, Yildirim Dogan, Malcolm A.S. Moore, Toshiyoshi Fujiwara, Toshifumi Ozaki, (unknown), John H. Healey	157
3	Mechanistic details of the actinobacterial lyase-catalyzed degradation reaction of 2-hydroxyisobutyryl-CoA 2021 ·Journal of Biological Chemistry ·Michael Zahn, Gerhard König, (unknown), (unknown), Ryszard Łaźny, Guangli Yang, Ouathek Ouerfelli, Zenon Łotowski, Thore Rohwerder	3
4	Synthesis of the PET Tracer ¹²⁴I-Trametinib for MAPK/ERK Kinase Distribution and Resistance Monitoring 2020 ·Journal of Nuclear Medicine ·Edwin C. Pratt, Elizabeth Isaac, (unknown), Guangbin Yang, Ouathek Ouerfelli, Nagavarakishore Pillarsetty, Jan Grimm	10
5	CRISPR-Cas III-A Csm6 CARF Domain Is a Ring Nuclease Triggering Stepwise cA4 Cleavage with ApA>p Formation Terminating RNase Activity 2019 ·Molecular Cell ·Ning Jia, Roger A. Jones, Guangli Yang, Ouathek Ouerfelli, Dinshaw J. Patel	98
6	The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression 2019 ·Cancer Cell ·Wenjing Su, Hyun Ho Han, Yan Wang, Boyu Zhang, Bing Zhou, Yuanming Cheng, (unknown), Sreeharsha Gurrapu, Goutam Chakraborty, Jie Su, Guangli Yang, Xin Liang, Guocan Wang, Neal Rosen, Howard I. Scher, Ouathek Ouerfelli, Filippo G. Giancotti	145
7	BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors 2018 ·Cell Reports ·Enrico Derenzini, Patrizia Mondello, Tatiana Erazo, (unknown), Yuxuan Liu, (unknown), Zahra Asgari, John Philip, Patrick Hilden, Debora Valli, Alessandra Rossi, Hakim Djaballah, Ouathek Ouerfelli, Elisa de Stanchina, Venkatraman Seshan, Ronald C. Hendrickson, Anas Younes	27
8	Evaluation of Glycodendron and Synthetically Modified Dextran Clearing Agents for Multistep Targeting of Radioisotopes for Molecular Imaging and Radioimmunotherapy 2013 ·Molecular Pharmaceutics ·Sarah M. Cheal, Barney Yoo, Sarah Boughdad, Blesida Punzalan, Guangbin Yang, (unknown), (unknown), Jun Pu, Don B. Axworthy, Pat Zanzonico, Ouathek Ouerfelli, Steven M. Larson	9
9	Activity-Based Metabolomic Profiling of Enzymatic Function: Identification of Rv1248c as a Mycobacterial 2-Hydroxy-3-oxoadipate Synthase 2010 ·Chemistry & Biology ·Luiz Pedro S. de Carvalho, Hong Zhao, Caitlyn Dickinson, (unknown), Christopher D. Lima, Steven M. Fischer, Ouathek Ouerfelli, Carl Nathan, Kyu Y. Rhee	86
10	Confirmation of the structures of synthetic derivatives of migrastatin in the light of recently disclosed crystallographically based claims 2010 ·Tetrahedron Letters ·Pavel Nagorny, Isaac J. Krauss, Jón T. Njardarson, (unknown), Christoph Gaul, Guangli Yang, Ouathek Ouerfelli, Samuel J. Danishefsky	18
11	Synthesis of Human Cancer Associated Globo-H (MBr1) Glycosylamino Acid: Some Mechanistic and Conformational Reinvestigations 2009 ·Heterocycles ·Samuel J. Danishefsky, Jianglong Zhu, Qian Wan, (unknown), Ouathek Ouerfelli	5
12	Radiosynthesis of [131I]IAZGP via nucleophilic substitution and its biological evaluation as a hypoxia marker — is specific activity a factor influencing hypoxia-mapping ability of a hypoxia marker? 2009 ·Nuclear Medicine and Biology ·Makiko Suehiro, Paul Burgman, Sean Carlin, Sean Burke, Guangbin Yang, Ouathek Ouerfelli, Christoph Oehler‐Jänne, Joseph A. O’Donoghue, Clifton C. Ling, John L. Humm	9
13	Structure and Activity of Human Mitochondrial Peptide Deformylase, a Novel Cancer Target 2009 ·Journal of Molecular Biology ·(unknown), Yehuda Goldgur, Guangli Yang, Ouathek Ouerfelli, Yueming Li, David A. Scheinberg	43
14	Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer 2009 ·Journal of Clinical Investigation ·Lucía Regales, Yixuan Gong, Ronglai Shen, Elisa de Stanchina, Igor Vivanco, Aviva Goel, Jason A. Koutcher, Maria Spassova, Ouathek Ouerfelli, Ingo K. Mellinghoff, Maureen F. Zakowski, Katerina Politi, William Pao	297
15	Stereo-controlled synthesis of novel photoreactive γ-secretase inhibitors 2008 ·Bioorganic & Medicinal Chemistry Letters ·Guangli Yang, Ye Yin, Jiong Chun, Christopher C. Shelton, Ouathek Ouerfelli, Yue‐Ming Li	11
16	High-Throughput Identification of Inhibitors of Human Mitochondrial Peptide Deformylase 2007 ·SLAS DISCOVERY ·Christophe Antczak, David Shum, (unknown), Bhramdeo Bassit, (unknown), Venkatraman Seshan, Nian Wu, Guangli Yang, Ouathek Ouerfelli, Yueming Li, David A. Scheinberg, Hakim Djaballah	32
17	Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors breakdown → 2006 ·Clinical Cancer Research ·Marissa N. Balak, Yixuan Gong, Gregory J. Riely, Romel Somwar, Allan R. Li, Maureen F. Zakowski, Anne C. Chiang, Guangli Yang, Ouathek Ouerfelli, Mark G. Kris, Marc Ladanyi, Vincent A. Miller, William Pao	664
18	Chemical inhibition of N-WASP by stabilization of a native autoinhibited conformation 2004 ·Nature Structural & Molecular Biology ·Jeffrey R. Peterson, (unknown), David M. L. Morgan, Annette S. Kim, Ouathek Ouerfelli, Marc W. Kirschner, Michael K. Rosen	157
19	Synthesis and evaluation of geldanamycin–testosterone hybrids 2000 ·Bioorganic & Medicinal Chemistry Letters ·Scott D. Kuduk, Christina R. Harris, Fuzhong F. Zheng, Laura Sepp‐Lorenzino, Ouathek Ouerfelli, Neal Rosen, Samuel J. Danishefsky	71
20	Transbilayer movement of Glc-P-dolichol and its function as a glucosyl donor: protein-mediated transport of a water-soluble analog into sealed ER vesicles from pig brain 1998 ·Glycobiology ·Jeffrey S. Rush, Klaus van Leyen, Ouathek Ouerfelli, Beata A. Wolucka, Charles J. Waechter	32

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact